A Randomized, Single-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Stimulatory Effects of TAK-448, a Kisspeptin Analog, Administered Intermittently in Middle-aged and Older Men With Low Testosterone
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs TAK 448 (Primary)
- Indications Testicular disorders
- Focus Pharmacokinetics
- Sponsors Takeda
- 08 Dec 2016 Status changed from recruiting to discontinued.
- 17 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 02 Sep 2015 Study design has been changed from double blind to single blind, number of arms changed from 5 to 4, drug dose has been changed - in cohort 1A: 0.3micrograms to0.1micrograms, cohort 1B: 1.0micrograms to 0.3micrograms, cohort 1C: 3micrograms to 1.0micrograms as reported by ClinicalTrials.gov record.